Market Newsdesk

RISHON LE ZION, Israel, Sept. 14, 2022 (GLOBE NEWSWIRE) — BOS Better Online Solutions Ltd. (“BOS” or the “Company”) (NASDAQ: BOSC) announced today that its Supply Chain Division has received an order for an amount of $2.7 million from an Israeli defense-industry customer.

Avidan Zelicovski, BOS’ President, stated: “This is an order from an existing Israeli customer for delivery through the year 2023. It is an addition to orders totaling $1.1 million that this client has placed since the beginning of the year. This order demonstrates the strong added value of our supply chain services to manufacturers from the defense industry. The Supply Chain division’s backlog has now increased to a record level of $20.2 million, as compared to a backlog of $8.9 million in September 2021.”

About BOS

BOS provides services and systems for inventory production and management in three channels:

• Services – The Supply Chain division provides inventory procurement and kitting.
• Integration – the RFID division provides off-the-shelf software and equipment to track and manage inventory in the production floor and warehouse.
• Development – the Intelligent Robotics division develops and builds custom-made robotic cells for the industrial and logistic processes.

Contact: Eyal Cohen, CEO
+972-542525925 | [email protected]

Safe Harbor Regarding Forward-Looking Statements

The forward-looking statements contained herein reflect management’s current views with respect to future events and financial performance. These forward-looking statements are subject to certain risks and uncertainties that could cause the actual results to differ materially from those in the forward-looking statements, all of which are difficult to predict and many of which are beyond the control of BOS. These risk factors and uncertainties include, amongst others, the dependency of sales being generated from one or few major customers, the uncertainty of BOS being able to maintain current gross profit margins, inability to keep up or ahead of technology and to succeed in a highly competitive industry, failure to successfully integrate and achieve the potential benefits of the acquisition of the business operations of Imdecol Ltd. (the Robotics business line) and Dagesh Inventory Counting and Maintenance Ltd., inability to maintain marketing and distribution arrangements and to expand our overseas markets, uncertainty with respect to the prospects of legal claims against BOS, the effect of exchange rate fluctuations, general worldwide economic conditions, the impact of the COVID-19 virus and continued availability of financing for working capital purposes and to refinance outstanding indebtedness; and additional risks and uncertainties detailed in BOS’ periodic reports and registration statements filed with the US Securities and Exchange Commission. BOS undertakes no obligation to publicly update or revise any such forward-looking statements to reflect any change in its expectations or in events, conditions or circumstances on which any such statements may be based, or that may affect the likelihood that actual results will differ from those set forth in the forward-looking statements.

Flywire’s integrated offering with Universitas XXI provides students a streamlined payment experience, from initial application through to tuition

Partnership aligns with Flywire’s commitment to continue expansion in Spain and Latin America

BOSTON and MADRID, Spain, Sept. 14, 2022 (GLOBE NEWSWIRE) — Today, Flywire Corporation (Flywire) (Nasdaq: FLYW) a global payments enablement and software company, is announcing the availability of its integration with Universitas XXI, a university management system focused on servicing higher education customers throughout Spain and Latin America. Universitas XXI will extend Flywire’s digital education payments platform into its student information system, enabling a seamless payment experience for students and administrators, and supporting both international and domestic payment flows.

Flywire integrates directly into the Universitas XXI software, helping universities to automatically power every transaction, ranging from initial application fees, all the way through to tuition payments. Within the familiar Universitas XXI software, students and families can easily track and make payments in native currencies, and university accounting professionals will be able to see and access all payment information within their system of record. Flywire plugs directly into the Universitas XXI platform, helping universities to streamline upgrades and to ensure complex compliance standards, as well as tax considerations, are always up to date.

Both Spain and Latin America continue to be a popular academic destination for international students. Boasting 76 universities, Spain is the top choice for students taking part in the EU’s Erasmus+ study abroad program, and in light of the Spanish government’s proposal to ease the visa requirement process for students and recent graduates, the country is committed to attracting additional international students. Likewise, Latin American universities are fortifying their strategies to recruit more inbound international students. The most recent research from UNESCO suggests that Latin American countries are receiving almost as many students as they are sending students abroad.

As the demand for higher education experiences in Spain and Latin America increases, there is mounting pressure on universities to provide a streamlined payment experience for students and families. According to a Flywire report of students in Spain and Latin America, students studying in Spain would like to see more flexible, simpler, and more affordable payment options. Of those surveyed in Flywire’s report, 86% believe that the ability to pay their tuition digitally, in their local currency, and/or via their preferred payment method, would improve their higher education experience and reduce the stress involved. Additionally, 80% of students in both Mexico and Peru believe paying for their tuition in installments would make their education more affordable.

For universities in Spain and Latin America, it can still be difficult to manage student payments originating from different countries and in different currencies. Finance teams would need to manage domestic and international payments in different systems, and reconciling international payments typically requires a lot of manual effort for university staff and can complicate student registration. This all creates complexity and friction for both students and university staff, which is exactly what the integration between Flywire and Universitas XXI solves.

For students and families, the integrated solution provides a highly-tailored, convenient and secure digital payment experience, which can be customized by university, country, and currency. For institutions, they can consolidate the multiple payment options they offer, which accelerates funds flow, eases reconciliation and streamlines operational efficiencies. Additionally, institutions can create custom payment plans to provide students and families with greater flexibility. Additional benefits of the integrated solution between Flywire and Universitas XXI for institutions include reduced inbound contact volume, accelerated processing around student visas, and significantly reduced merchant processing fees thanks to more payment options.

“As Flywire continues our growth in Spain and Latin America, we’re thrilled to partner with Universitas XXI, who bring meaningful relationships with reputable universities and extensive knowledge of the Spanish and Latin American markets,” said Sharon Butler, EVP of Education at Flywire. “Through our powerful, seamless integration, we are able to deliver exceptional payment experiences for students and institutions alike – and we’re committed to building on this foundation as the partnership continues.”

“Our integration with Flywire enables us to elevate our offerings and provide even greater value to our customers,” said Manuel Rivera, Director of Communication and Marketing at Universitas XXI. “We look forward to our continued partnership to better serve the Spanish and Latin American markets.”

Resources

• Stop by Flywire’s booth G10 at the European Association for International Education (EAIE) event in Barcelona, Spain from 14 – 16 September
• Join Flywire and Universitas XXI together on a webinar to discuss the power of their partnership on October 13, 2022: Join Webinar
• Learn more about Flywire’s digital payments platform for higher education: Flywire’s digital education payments platform
• See why Flywire is the trusted choice for millions of students, thousands of institutions and hundreds of education agents and partners worldwide: The Trusted Choice

About Flywire

Flywire is a global payments enablement and software company. We combine our proprietary global payments network, next-gen payments platform and vertical-specific software to deliver the most important and complex payments for our clients and their customers.

Flywire leverages its vertical-specific software and payments technology to deeply embed within the existing A/R workflows for its clients across the education, healthcare and travel vertical markets, as well as in key B2B industries. Flywire also integrates with leading ERP systems, such as NetSuite, so organizations can optimize the payment experience for their customers while eliminating operational challenges.

Flywire supports more than 2,800 clients with diverse payment methods in more than 140 currencies across 240 countries and territories around the world. Flywire is headquartered in Boston, MA, USA with global offices. For more information, visit www.flywire.com. Follow Flywire on Twitter, LinkedIn and Facebook.

About Universitas XXI

Universitas XXI is a Spanish multinational that offers technological solutions to universities in Spain and Latin America. More than 100 universities operate daily with the Universitas XXI systems. To learn more visit: www.universitasxxi.com.

Safe Harbor Statement

This release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements regarding Flywire’s future operating results and financial position, Flywire’s business strategy and plans, and market growth and trends. Flywire intends such forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995. In some cases, you can identify forward-looking statements by terms such as, but not limited to, “believe,” “may,” “will,” “potentially,” “estimate,” “continue,” “anticipate,” “intend,” “could,” “would,” “project,” “target,” “plan,” “expect,” or the negative of these terms, and similar expressions intended to identify forward-looking statements. Such forward-looking statements are based upon current expectations that involve risks, changes in circumstances, assumptions, and uncertainties. Important factors that could cause actual results to differ materially from those reflected in Flywire’s forward-looking statements. New risks emerge from time to time. It is not possible for Flywire to predict all risks, nor can Flywire assess the impact of all factors on Flywire’s business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements Flywire may make. Further information on these and additional risks are described in the “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” sections of Flywire’s Annual Report on Form 10-K for the year ended December 31, 2021 and Quarterly Report on Form 10-Q for the quarter ended June 30, 2022, which are on file with the Securities and Exchange Commission (SEC) and available on the SEC’s website at 



https://www.sec.gov/



. Any forward-looking statements made by Flywire in this news release are based on information available to Flywire on the date hereof. Flywire assumes no obligation to, and does not currently intend to, update any such forward-looking statements after the date of this release.

Contacts

Media Contacts:

Sarah King
[email protected]

Prosek Partners
[email protected]

Investor Relations Contact:
ICR
[email protected]

MIRAMAR, FL, Sept. 14, 2022 (GLOBE NEWSWIRE) — Stemtech Corporation (“Stemtech”) (OTCQB: STEK), an innovative nutraceutical company and a pioneer in the field of stem cell nutrition, today announced the Go-Live date of their Stemtech Advance Office based on the VERB Technology Company, Inc. (NASDAQ: VERB) system.

Stemtech Corporation President and Chief Operating Officer, John W. Meyer, said “we are extremely happy to announce go-live for Monday, September 19, 2022. It is with great anticipation that we offer this exceptional, leading-edge industry software as a tremendous communication tool for our Independent Business Partners (IBPs). We are proud to have this partnership with VERB, who provide Stemtech with direct sales recruiting, retention and expansion of business capabilities. The analytics and communication aspects via their interactive video-based sales applications, including live-streaming, are a powerful means to communicate with new prospective customers. This partnership with such a prominent provider is an exciting step and will help drive momentum for Stemtech.”

A
bout
Stemtech Corporation

Stemtech Corporation, a leading nutraceutical company with a direct sales distribution model, was founded on April 18, 2018, after acquiring the operations from its predecessor Stemtech International, Inc. which was founded in 2005. From 2010 through 2015, Stemtech International, Inc., was recognized four separate times on the Inc. 5000 Fastest-Growing Companies list. In 2018, the Company underwent an extensive executive reorganization, and continued operations under new leadership. Stemtech specializes in creating products and formulas that are patent protected in the U.S. and in select international markets. The Company’s patented formulas help the release, circulation and migration of the body’s adult stem cells from its bone marrow. The Company markets its products under the following brands: RCM System, stemrelease3^™, Stemflo^® MigraStem, OraStem^® (Oral Health Care), and D-Fuze^™ (EMF blocker). Its nutraceutical products are all-natural, plant-based and manufactured under cGMP (Current Good Manufacturing Practices) under the auspices of the Dietary Supplement Health and Education Act (DSHEA). For more information, please visit www.stemtech.com.

About VERB Technology

Verb Technology Company, Inc. (Nasdaq: VERB), the market leader in interactive video-based sales applications, transforms how businesses attract and engage customers. The Company’s Software-as-a-Service, or SaaS, platform is based on its proprietary interactive video technology, and is comprised of a suite of sales enablement business software products offered on a subscription basis. Its software applications are used by hundreds of thousands of people in over 100 countries and in more than 48 languages. VERB’s clients include large sales-based enterprises as well as small business sales teams, including the sales and marketing departments of professional sports teams. MARKET.live is VERB’s multi-vendor, multi-presenter, livestream social shopping platform at the forefront of the convergence of ecommerce and entertainment. With approximately 150 employees and contractors, the Company is headquartered in Lehi, Utah, and also maintains offices in Newport Beach, California.

Forward-Looking Statements

This announcement contains forward-looking statements within the meaning of the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. Such statements include but are not limited to statements identified by words such as “believes,” “expects,” “anticipates,” “estimates,” “intends,” “plans,” “targets,” “projects” and similar expressions. The statements in this release are based upon the current beliefs and expectations of our company’s management and are subject to significant risks and uncertainties. Actual results may differ from those set forth in the forward-looking statements. Numerous factors could cause or contribute to such differences, including, but not limited to, results of clinical trials and/or other studies, the challenges inherent in new product development initiatives, the effect of any competitive products, our ability to license and protect our intellectual property, our ability to raise additional capital in the future that is necessary to maintain our business, changes in government policy and/or regulation, potential litigation by or against us, any governmental review of our products or practices, as well as other risks discussed from time to time in our filings with the Securities and Exchange Commission, including, without limitation, our latest 10-Q Report filed on August 23, 2022. We undertake no duty to update any forward-looking statement, or any information contained in this press release or in other public disclosures at any time. Finally, the investing public is reminded that the only announcements or information about Stemtech Corporation which are condoned by the Company must emanate from the Company itself and bear our name as its Source.

www.Stemtech.com

Stemtech
I
nvestor Relations

Phone: 954-715-6000 ext 1040
Email: [email protected]

BELLINGHAM, Wash., Sept. 14, 2022 (GLOBE NEWSWIRE) — eXp Realty^®, the fastest-growing global real estate brokerage and the core subsidiary of eXp World Holdings, Inc. (Nasdaq: EXPI), today announced plans to expand its real estate operations into Poland.

This announcement follows the successful launch of four new markets in 2022 including the Dominican Republic, Greece, New Zealand and Chile with Dubai expected to open soon. Upon launch of these new markets, eXp Realty will have a presence in 24 global markets, including its headquarters in the United States.

“Poland’s recent wave of real estate brokerage consolidation speaks to the attractiveness of its property sector for both foreign and domestic investments,” said Michael Valdes, Chief Growth Officer. “With continued rapid growth and resilience in the real estate market, Poland provides eXp Realty an ideal opportunity to establish a strong foothold in the Central and Eastern European region.”

eXp Realty’s brokerage operations in Poland will be led by Dorota Chomuntowska who joins the company with more than 11 years of real estate broker experience in Poland and other international markets. “eXp has pioneered a new wave of quality and value for the real estate industry,” says Chomuntowska. “I am honored to lead this expansion in Poland and look forward to introducing eXp Realty to agents across the country.”

About eXp World Holdings, Inc.

eXp World Holdings, Inc. (Nasdaq: EXPI) is the holding company for eXp Realty^®, Virbela and SUCCESS^® Enterprises.

eXp Realty is the fastest-growing real estate company in the world with more than 84,000 agents in the United States, Canada, the United Kingdom, Australia, South Africa, India, Mexico, Portugal, France, Puerto Rico, Brazil, Italy, Hong Kong, Colombia, Spain, Israel, Panama, Germany, Dominican Republic, Greece, New Zealand and Chile and continues to scale internationally. As a publicly traded company, eXp World Holdings provides real estate professionals the unique opportunity to earn equity awards for production goals and contributions to overall company growth. eXp World Holdings and its businesses offer a full suite of brokerage and real estate tech solutions, including its innovative residential and commercial brokerage model, professional services, collaborative tools and personal development. The cloud-based brokerage is powered by Virbela, an immersive 3D platform that is deeply social and collaborative, enabling agents to be more connected and productive. SUCCESS^® Enterprises, anchored by SUCCESS^® magazine and its related media properties, was established in 1897 and is a leading personal and professional development brand and publication.

For more information, visit https://expworldholdings.com.

Safe Harbor Statement

The statements contained herein may include statements of future expectations and other forward-looking statements that are based on management’s current views and assumptions and involve known and unknown risks and uncertainties that could cause actual results, performance or events to differ materially from those expressed or implied in such statements. Such forward-looking statements speak only as of the date hereof, and the company undertakes no obligation to revise or update them. These statements include, but are not limited to, statements about the continued growth of our agent and broker base; expansion of our residential real estate brokerage business into foreign markets; demand for remote working and distance learning solutions and virtual events; development of our commercial brokerage and our ability to attract commercial real estate brokers; and revenue growth and financial performance. Such statements are not guarantees of future performance. Important factors that may cause actual results to differ materially and adversely from those expressed in forward-looking statements include changes in business or other market conditions; the difficulty of keeping expense growth at modest levels while increasing revenues; and other risks detailed from time to time in the company’s Securities and Exchange Commission filings, including but not limited to the most recently filed Quarterly Report on Form 10-Q and Annual Report on Form 10-K.

Media Relations Contact:

eXp World Holdings, Inc.

[email protected]

Investor Relations Contact:

Denise Garcia

[email protected]

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/c875c384-146a-4461-abe2-0cc37ed07571

BOSTON and DURHAM, N.C., Sept. 14, 2022 (GLOBE NEWSWIRE) — Parexel, a leading global clinical research organization (CRO), today announced the promotions of Peyton Howell to the newly-created role of Chief Operating and Growth Officer and Amy McKee, MD, to Chief Medical Officer and Global Head, Oncology Center of Excellence. These moves are designed to strengthen the company’s medical and scientific focus and support its continued record growth through closer alignment of all aspects of strategy, sales and delivery to delight customers, build repeat business and lead the market in the next phase of drug development transformation.

As Chief Operating and Growth Officer, Ms. Howell will lead Parexel’s operational delivery, strategy and growth. She joined Parexel in May 2018 and most recently was President, Consulting and Chief Commercial & Strategy Officer, leading the company to record new business growth and creation of a patient-focused strategy. In addition to providing strategic oversight for the rebranding of Parexel in 2019, Ms. Howell was a key architect in the launch of the organization’s new Business Strategy and has consistently led Parexel’s global Biotech and Enterprise Commercial teams to record new business growth.

“As the market evolves, we continuously review our structure to ensure Parexel remains well positioned to deliver integrated and innovative solutions for our patients and customers,” said Chief Executive Officer Jamie Macdonald. “The promotion of Peyton Howell to this expanded role is a natural extension of her significant contributions to the growth of Parexel over the past four years and along with her tremendous energy and passion for serving our customers, patients and colleagues. Broadening the scope of her strategic leadership to now include our operational delivery units further enhances the support we’re able to provide to our customers’ development programs. We’re excited for this next chapter and wish both Peyton and Amy every success in their new roles.”

Ms. Howell has more than 25 years of leadership experience in the healthcare industry, including several leadership positions with AmerisourceBergen, a Fortune 20 company, most recently as President for Health Systems and Specialty Care Solutions, a $50B business unit. Currently she represents Parexel on the Board of Directors for the Association of Clinical Research Organizations (ACRO) and serves on the Board of Directors of Tandem Diabetes Care (NASDAQ:TNDM), a medical device manufacturer. Ms. Howell holds a Masters’ in Healthcare Administration (MHA) from The Ohio State University and in 2020 was named a Luminary by the Healthcare Businesswomen’s Association (HBA).

As Chief Medical Officer and Global Head, Oncology Center of Excellence, Dr. McKee will provide patient-focused medical and scientific leadership globally in support of the company’s Phase I to IV clinical trials. With nearly 20 years of FDA regulatory, clinical research, bench science and clinical medicine experience, she will provide strategic oversight for the company’s therapeutic/medical and scientific centers of excellence to drive growth and innovation, including collaboration with key stakeholders to strengthen Parexel as a collaborative drug development partner and establish market-leading, patient-centered teams.

“We are thrilled to appoint Amy as our new Chief Medical Officer as we expand our therapeutic expertise to align with the fastest-growing areas of patient need,” added Peyton Howell, Chief Operating and Growth Officer. “With her proven track record in the design and implementation of complex and innovative clinical development programs across a broad spectrum of therapeutic areas — with a particular specialization in oncology — we have no doubt Amy will have a tremendous impact as we accelerate innovations to bring new therapies to patients.”

Dr. McKee joined Parexel in February 2019 as Vice President, Regulatory Consulting Services and prior to joining the company spent 11 years with the FDA during which time she served as Deputy Center Director, Oncology Center of Excellence; Supervisory Associate Director, Office of Hematology and Oncology Products (OHOP) and Deputy Office Director of OHOP. She is a board-certified Pediatric Hematologist-Oncologist with specific expertise in the treatment of neuroblastoma and holds a Doctor of Medicine degree from the Tulane University School of Medicine in New Orleans, La. Dr. McKee currently serves on the Board of Directors for BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX).

About Parexel

One of the largest clinical research organizations, Parexel supports the development of innovative new medicines to improve the health of patients. We provide services to help life sciences and biopharmaceutical customers everywhere transform scientific discoveries into new treatments. From decentralized clinical trials to regulatory consulting services to leveraging real world insights, our therapeutic, technical and functional ability is underpinned by a deep conviction in what we do. For more information, visit parexel.com and follow us on LinkedIn, Twitter, and Instagram.

MEDIA

Lori Preuit Dorer
+1 513 496 8121
[email protected]

Danaka Williams
+1 984 298 4207
[email protected]

SAN MATEO, Calif., Sept. 14, 2022 (GLOBE NEWSWIRE) — Backblaze, Inc. (Nasdaq: BLZE), the leading independent storage cloud platform, will be presenting at the Sidoti September Small Cap Virtual Investor Conference on Wednesday, September 21, 2022. Co-founder, CEO and Chairperson of the Board Gleb Budman and CFO Frank Patchel will be presenting via webcast from 10:45 a.m. to 11:15 am PT (1:45 pm to 2:15 pm ET).

Investors may attend the webcast by visiting the Events section of Backblaze’s investor relations website at https://ir.backblaze.com/news-events/events-presentations. An archive of the webcast will be available shortly after its completion and will be accessible for 90 days.

About Backblaze

Backblaze makes it astonishingly easy to store, use, and protect data. The Backblaze Storage Cloud provides a foundation for businesses, developers, IT professionals, and individuals to build applications, host content, manage media, back up and archive data, and more. With over two billion gigabytes of data storage under management, the company currently works with more than 500,000 customers in over 175 countries. Founded in 2007, the company is based in San Mateo, CA. For more information, please go to www.backblaze.com. 

Investors

James Kisner, CFA
Vice President, Investor Relations and Corporate Development
[email protected]

Press Contact

Jeanette Foster
Communications Manager
[email protected]

MINNEAPOLIS, Sept. 14, 2022 (GLOBE NEWSWIRE) — Fresh Vine Wine, Inc. (NYSE American: VINE), the premier producer of lower carb, lower sugar, and lower calorie premium wines in the United States, today announced that Food Lion has added its California Cabernet Sauvignon varietal to its ‘Limited Reserve’ program at 225 Food Lion grocery locations in North Carolina, South Carolina, and Virginia.

“I am delighted to announce that Food Lion has chosen Fresh Vine Wine’s 92 point rated California Cabernet Sauvignon as the newest addition to its celebrated ‘Limited Reserve’ collection of fine wines,” said Bill Donovan, East Atlantic Division Manager, Fresh Vine Wine. “Food Lion enjoys a leading position in the Grocery Market in its geographic markets, where it is focused on offering its customers fresh, healthy food and beverage choices. The introduction of our ‘Better For You’ California Cabernet Sauvignon furthers their effort to meet this growing demand for healthy choices without compromising taste. As part of our national grocery channel rollout strategy, Food Lion complements our existing footprint and provides us with premier retail distribution in the Southeastern U.S.”

Fresh Vine Wine’s vision is to be the leading “Better For You” brand in this emerging category, capitalizing on the trend toward healthy living that is sweeping the food and beverage industry. Fresh Vine Wine’s strategy is to accelerate growth in 2022 by amplifying its product offerings, actively growing distribution, educating consumers and retailers on our premium product line, and focusing on in-market retail execution and in-store samplings. Fresh Vine Wine will continue to position its core brand lineup as an affordable luxury, between $14.99-$24.99. Sauvignon Blanc and Brut Rosé Sparkling are Fresh Vine Wine’s latest entry into the premium wine market. 

Press contact – [email protected]
IR contact – [email protected]

About Fresh Vine Wine, Inc.

Fresh Vine Wine, Inc. (NYSE American: VINE) is a premier producer of lower carb, lower calorie premium wines in the United States, kicking off a 2022 growth plan following its IPO in mid-December 2021. Fresh Vine Wine’s brand vision is to lead the emerging natural and accessible premium wine category, as health trends continue to accelerate in the US marketplace. The 2020 US wine market was a $69 billion category. Fresh Vine Wine plans to accelerate growth in 2022 by amplifying its marketing, expanding product offerings, and expanding its team. Fresh Vine Wine positions its core brand lineup as an affordable luxury, retailing between $14.99-$24.99. Fresh Vine Wine’s varietals currently include Limited Reserve Cabernet Sauvignon, Cabernet Sauvignon, Chardonnay, Sauvignon Blanc, Pinot Noir, Brut Rosé Sparkling, and Rosé. 

About Food Lion

Food Lion is an omnichannel retailer committed to nourishing its neighbors during the moments that matter most. More than 82,000 associates across 1,100+ stores deliver an easy, fresh, and affordable shopping experience throughout 10 Southeastern and Mid-Atlantic states.   More information can be found at foodlion.com.

MIRAMAR, Fla., Sept. 14, 2022 (GLOBE NEWSWIRE) — Stemtech Corporation (“Stemtech”) (OTCQB: STEK), an innovative nutraceutical company and a pioneer in the field of stem cell nutrition, today announced the Go-Live date of their Stemtech Advance Office based on the VERB Technology Company, Inc. (NASDAQ: VERB) system.

Stemtech Corporation President and Chief Operating Officer, John W. Meyer, said “we are extremely happy to announce go-live for Monday, September 19, 2022. It is with great anticipation that we offer this exceptional, leading-edge industry software as a tremendous communication tool for our Independent Business Partners (IBPs). We are proud to have this partnership with VERB, who provide Stemtech with direct sales recruiting, retention and expansion of business capabilities. The analytics and communication aspects via their interactive video-based sales applications, including live-streaming, are a powerful means to communicate with new prospective customers. This partnership with such a prominent provider is an exciting step and will help drive momentum for Stemtech.”

About Stemtech Corporation

Stemtech Corporation, a leading nutraceutical company with a direct sales distribution model, was founded on April 18, 2018, after acquiring the operations from its predecessor Stemtech International, Inc. which was founded in 2005. From 2010 through 2015, Stemtech International, Inc., was recognized four separate times on the Inc. 5000 Fastest-Growing Companies list. In 2018, the Company underwent an extensive executive reorganization, and continued operations under new leadership. Stemtech specializes in creating products and formulas that are patent protected in the U.S. and in select international markets. The Company’s patented formulas help the release, circulation and migration of the body’s adult stem cells from its bone marrow. The Company markets its products under the following brands: RCM System, stemrelease3^™, Stemflo^® MigraStem, OraStem^® (Oral Health Care), and D-Fuze^™ (EMF blocker). Its nutraceutical products are all-natural, plant-based and manufactured under cGMP (Current Good Manufacturing Practices) under the auspices of the Dietary Supplement Health and Education Act (DSHEA). For more information, please visit www.stemtech.com.

About VERB Technology

Verb Technology Company, Inc. (Nasdaq: VERB), the market leader in interactive video-based sales applications, transforms how businesses attract and engage customers. The Company’s Software-as-a-Service, or SaaS, platform is based on its proprietary interactive video technology, and is comprised of a suite of sales enablement business software products offered on a subscription basis. Its software applications are used by hundreds of thousands of people in over 100 countries and in more than 48 languages. VERB’s clients include large sales-based enterprises as well as small business sales teams, including the sales and marketing departments of professional sports teams. MARKET.live is VERB’s multi-vendor, multi-presenter, livestream social shopping platform at the forefront of the convergence of ecommerce and entertainment. With approximately 150 employees and contractors, the Company is headquartered in Lehi, Utah, and also maintains offices in Newport Beach, California.

Forward-Looking Statements

This announcement contains forward-looking statements within the meaning of the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. Such statements include but are not limited to statements identified by words such as “believes,” “expects,” “anticipates,” “estimates,” “intends,” “plans,” “targets,” “projects” and similar expressions. The statements in this release are based upon the current beliefs and expectations of our company’s management and are subject to significant risks and uncertainties. Actual results may differ from those set forth in the forward-looking statements. Numerous factors could cause or contribute to such differences, including, but not limited to, results of clinical trials and/or other studies, the challenges inherent in new product development initiatives, the effect of any competitive products, our ability to license and protect our intellectual property, our ability to raise additional capital in the future that is necessary to maintain our business, changes in government policy and/or regulation, potential litigation by or against us, any governmental review of our products or practices, as well as other risks discussed from time to time in our filings with the Securities and Exchange Commission, including, without limitation, our latest 10-Q Report filed on August 23, 2022. We undertake no duty to update any forward-looking statement, or any information contained in this press release or in other public disclosures at any time. Finally, the investing public is reminded that the only announcements or information about Stemtech Corporation which are condoned by the Company must emanate from the Company itself and bear our name as its Source.

www.Stemtech.com

Investor Relations:

Frank J. Pena, 908 675-0581                
[email protected]

NO-HEADQUARTERS/REDWOOD CITY, Calif., Sept. 14, 2022 (GLOBE NEWSWIRE) — PubMatic (Nasdaq: PUBM), an independent technology company delivering digital advertising’s supply chain of the future, today announced that it has entered into a definitive agreement to acquire Martin, a media measurement and reporting platform, deepening the company’s investment in supply path optimization (SPO).

“The digital advertising supply chain of the future must be efficient and effective for both publishers and buyers alike. To this end, over the past several years we have been investing in technology and solutions to enable buyers to efficiently access inventory and audiences from top publishers around the globe,” said Rajeev Goel, co-founder and CEO at PubMatic. “By integrating Martin’s robust workflow, analytics and optimization capabilities for advertisers and agencies into our platform, we believe we will further accelerate and solidify our position as the platform of choice for buyers, and in turn bring greater advertising revenue to our global publisher base.”

The acquisition is in response to growing demand from PubMatic’s buy-side customers for enhanced tools to take advantage of PubMatic’s global omnichannel inventory, including market-leading addressability solutions like Connect and innovative technology to enable SPO.

“We are thrilled to join PubMatic, a leader in programmatic technology and innovation. As the industry matures, it’s more important than ever to deliver transparent insights to buyers in order to improve their ability to reach their audiences on quality content,” said Tanja Mimica, CEO and co-founder at Martin. “I am excited for our extremely talented team to join the PubMatic family where we can continue to innovate as part of PubMatic’s SPO product roadmap.”

The transaction will be fully funded from existing cash on PubMatic’s balance sheet, and is expected to close in mid-September 2022, subject to customary closing conditions.

About Martin

Martin is a media measurement and reporting platform that delivers customized solutions for sophisticated buyers to increase return on media spend.

About PubMatic

PubMatic (Nasdaq: PUBM) is an independent technology company maximizing customer value by delivering digital advertising’s supply chain of the future. PubMatic’s sell-side platform empowers the world’s leading digital content creators across the open internet to control access to their inventory and increase monetization by enabling marketers to drive return on investment and reach addressable audiences across ad formats and devices. Since 2006, our infrastructure-driven approach has allowed for the efficient processing and utilization of data in real time. By delivering scalable and flexible programmatic innovation, we improve outcomes for our customers while championing a vibrant and transparent digital advertising supply chain.

Cautionary Note Regarding Forward-Looking Statements

This press release contains forward-looking statements within the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical fact, including statements regarding the anticipated benefits of the transaction, are forward-looking statements. Forward-looking statements are based on management’s expectations, assumptions, and projections based on information available at the time the statements were made. These forward-looking statements are subject to a number of risks, uncertainties, and assumptions, including, without limitation, risk related to the ability of the parties to satisfy the closing conditions in a timely fashion or at all, risks related to the integration of Martin into PubMatic, risk related to the potential impact on Martin’s business and business relationships as a result of the transaction and risk related to the ability of PubMatic and Martin to retain and motivate key employees. It is not possible for PubMatic’s management to predict all risks, nor can PubMatic assess the impact of all factors on PubMatic’s business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements PubMatic may make. In light of these risks, uncertainties, and assumptions, the actual results could differ materially and adversely from those anticipated or implied in the forward-looking statements. For more information about risks and uncertainties that could cause actual results to differ materially from the forward-looking statements, please refer to PubMatic’s Annual Report on Form 10-K for the year ended December 31, 2021, its Quarterly Report on Form 10-Q for the quarter ended June 30, 2022, and its other filings with the Securities and Exchange Commission (SEC), which are available on the SEC’s website at www.sec.gov. PubMatic undertakes no obligation to update any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by law.

Press Contact:

Broadsheet Communications for PubMatic
[email protected]
(917) 826-1103

– Registrational studies planned to start in 4Q 2022 –

– Two-year data from Phase 2a Open Label Extension study expected in 4Q 2022 –

BOSTON and LONDON, Sept. 14, 2022 (GLOBE NEWSWIRE) — Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage pharmaceutical company with a Research & Development (“R&D”) innovation engine that aims to discover, develop, and ultimately deliver impactful medicines to patients, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to SerpinPC, a novel inhibitor of activated protein C (“APC”), for the treatment of hemophilia B. Centessa plans to begin registrational studies of SerpinPC in the fourth quarter of 2022.

SerpinPC is a biological drug candidate, based on the serpin family of proteins that is designed to allow more thrombin to be generated by inhibiting APC, thus rebalancing coagulation in hemophilia patients. In September 2021, Centessa announced positive topline data from its proof-of-concept Phase 2a study of SerpinPC in severe hemophilia A and B patients not on prophylaxis. In the highest dose cohort, SerpinPC demonstrated an 88% reduction in median Annualized Bleeding Rate (ABR) for all bleeds and a 94% reduction in median ABR for spontaneous joint bleeds. SerpinPC was observed to be well-tolerated with no thrombosis and no instances of sustained D-dimer elevations.

“We believe SerpinPC has the potential to offer patients with hemophilia B a convenient subcutaneous option that is designed to prevent and reduce bleeds without the risk of thrombosis,” said Saurabh Saha, MD, PhD, Chief Executive Officer of Centessa. “This designation from the FDA is an important milestone in the development of SerpinPC and underscores the need for new, innovative treatment options for patients with hemophilia B. We look forward to initiating registrational studies for SerpinPC later this year, as well as reporting the two-year follow-up data from the SerpinPC Phase 2a open label extension study in the fourth quarter.”

Orphan Drug Designation is granted by the FDA to drugs or biologics intended to treat a rare disease or condition, defined as one that affects fewer than 200,000 people in the U.S. Orphan Drug Designation provides certain financial incentives to support clinical development, and the potential for up to seven years of marketing exclusivity for the product for the designated orphan indication in the U.S. if the product is ultimately approved for its designated indication.

About Centessa
Pharmaceuticals

Centessa Pharmaceuticals plc is a clinical-stage pharmaceutical company with an R&D innovation engine that aims to discover, develop, and ultimately deliver impactful medicines to patients. Our programs span discovery-stage to late-stage development and cover a range of high-value indications in rare diseases and immuno-oncology. We are led by a management team with extensive R&D experience, providing direct guidance to our program teams to rapidly advance our candidates from research through all stages of development. For more information, visit www.centessa.com, which does not form part of this release.

Forward Looking Statements

This press release contains forward-looking statements. These statements may be identified by words such as “may,” “might,” “will,” “could,” “would,” “should,” “expect,” “intend,” “plan,” “objective,” “anticipate,” “believe,” “estimate,” “predict,” “potential,” “continue,” “ongoing,” “aim,” “seek,” and variations of these words or similar expressions that are intended to identify forward-looking statements. Any such statements in this press release that are not statements of historical fact may be deemed to be forward-looking statements, including statements related to the Company’s ability to deliver impactful medicines to patients; the ability of our management team and board to drive execution of the Company’s portfolio of programs; our asset-centric business model and the intended advantages and benefits thereof; research and clinical development plans and the timing thereof; the scope, progress, results and costs of developing our product candidates or any other future product candidates; the development and therapeutic potential of our product candidates, including SerpinPC; strategy; regulatory matters, including the timing and likelihood of initiating clinical trials, reporting clinical trial results, submitting an IND and the success of obtaining authorizations to initiate or continue clinical trials or market any products; and the market size and opportunity for our product candidates. Any forward-looking statements in this press release are based on our current expectations, estimates and projections only as of the date of this release and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to, risks related to the safety and tolerability profile of our product candidates; our ability to protect and maintain our intellectual property position; business (including commercial viability), regulatory, economic and competitive risks, uncertainties, contingencies and assumptions about the Company; risks inherent in developing product candidates and technologies; future results from our ongoing and planned clinical trials; our ability to obtain adequate financing, including through our financing facility with Oberland, to fund our planned clinical trials and other expenses; trends in the industry; the legal and regulatory framework for the industry, including the receipt and maintenance of clearances to conduct or continue clinical testing; future expenditures risks related to our asset-centric corporate model; the risk that any one or more of our product candidates will not be successfully developed and/or commercialized; the risk that the results of non-clinical studies or clinical studies will not be predictive of future results in connection with future studies; geo-political risks such as the Russia-Ukraine war and risks related to the ongoing COVID-19 pandemic including the effects of the Delta, Omicron and any other variants. These and other risks concerning our programs and operations are described in additional detail in our Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, and our other reports, which are on file with the U.S. Securities and Exchange Commission (SEC). We explicitly disclaim any obligation to update any forward-looking statements except to the extent required by law.

Contact:

Kristen K. Sheppard, Esq.
SVP of Investor Relations
[email protected]